U.S. AI-Enabled Diabetes Care Devices Market

Market Outlook

By 2035, the U.S. AI-Enabled Diabetes Care Devices Market is projected to reach approximately USD 35.62 billion, expanding at a CAGR of 17.26% during the forecast period 2026–2035. The market is estimated at USD 7.25 billion in 2025, following expansion from approximately USD 3.25 billion in 2021, USD 3.88 billion in 2022, USD 4.70 billion in 2023, and USD 5.76 billion in 2024. Values in this report are expressed in USD billions.

For this report, market value represents U.S. revenue attributable to diabetes care devices in which artificial intelligence, machine learning, predictive algorithms, adaptive dosing logic, automated insulin delivery, sensor-fusion analytics, or algorithm-driven clinical decision support materially contributes to the product’s clinical or commercial value. The scope includes AI-enabled continuous glucose monitoring systems, automated insulin delivery systems, smart insulin pumps, connected insulin dosing devices, intelligent glucose meters and biosensors, and device-linked decision-support platforms. Generic smartphones, diabetes pharmaceuticals, conventional glucose meters without meaningful algorithmic functionality, and standalone wellness applications are excluded.

The market is moving rapidly from passive glucose measurement toward predictive and increasingly autonomous diabetes management. Conventional monitoring tells a patient what glucose has already done. AI-enabled devices are designed to interpret where glucose is heading, estimate insulin requirements, detect patterns that may otherwise be missed, personalize treatment parameters, and automate selected therapeutic actions. That shift materially increases the economic value of the device ecosystem because manufacturers can participate across sensor replacement, insulin delivery, software, analytics, patient engagement, and remote clinical management.

The U.S. addressable population remains exceptionally large. More than 40 million people are estimated to be living with diagnosed or undiagnosed diabetes, while more than 115 million U.S. adults have prediabetes. Approximately 29 million people have diagnosed diabetes, and more than 2 million Americans are estimated to have diagnosed type 1 diabetes. These populations create multiple adoption pools: intensive insulin users requiring automated dosing, type 2 patients using basal insulin, non-insulin-treated patients adopting CGM, people at elevated hypoglycemia risk, and consumers using glucose biosensors for metabolic awareness.

Growth will accelerate as AI capabilities move beyond premium pump users. FDA expansion of automated insulin delivery into type 2 diabetes, broader Medicare CGM eligibility, over-the-counter glucose biosensors, predictive dosing software, longer-wear sensors, pharmacy-channel distribution, and interoperable device architectures are substantially widening the commercial funnel.

Under the report’s base-case aggressive adoption scenario, the market is expected to reach approximately USD 8.50 billion in 2026 and USD 16.07 billion by 2030, before advancing to USD 35.62 billion in 2035. Expansion will increasingly depend on how successfully manufacturers extend algorithmic diabetes management from specialist endocrinology into primary care and from intensive insulin therapy into the much larger type 2 diabetes population.

Introduction

According to the U.S. AI-Enabled Diabetes Care Devices Market Report, artificial intelligence is becoming a foundational layer of modern diabetes technology rather than a standalone feature. Its commercial importance comes from the ability to convert continuous streams of glucose, insulin, meal, activity, medication, and behavioral information into clinically useful recommendations or automated treatment actions.

The U.S. diabetes care ecosystem is particularly suited to AI-enabled devices because it combines a large chronic disease population, sophisticated reimbursement infrastructure, widespread smartphone use, mature pharmacy distribution, specialist endocrinology networks, substantial Medicare exposure, established continuous glucose monitoring adoption, and a highly competitive medical technology industry.

AI-enabled diabetes care is already visible in automated insulin delivery. Modern systems can continuously evaluate CGM readings, anticipate glucose movement, modify basal insulin, provide correction dosing, and reduce the number of decisions required from patients. FDA-cleared technologies have increasingly expanded automated dosing beyond type 1 diabetes, creating a commercially important pathway into insulin-requiring type 2 diabetes.

Continuous glucose monitoring is simultaneously becoming the data foundation for the broader AI ecosystem. Each sensor generates dense longitudinal glucose information that can support trend recognition, meal-response analysis, hypoglycemia prediction, insulin optimization, remote monitoring, and individualized behavioral guidance. As sensor duration increases and wearability improves, the volume and continuity of usable patient data increase correspondingly.

The economics of diabetes create strong incentives for this transition. Diabetes produces substantial direct medical expenditure as well as productivity losses, disability, cardiovascular complications, kidney disease, neuropathy, retinopathy, severe hypoglycemia, diabetic ketoacidosis, and avoidable hospitalization. Technologies that can improve time in range, identify deterioration earlier, simplify insulin management, or reduce acute episodes therefore have value beyond the physical device.

The customer base is also broadening. Historically, advanced diabetes devices were concentrated among people with type 1 diabetes under endocrinology care. The future market will be substantially more heterogeneous. It will include adults with insulin-treated type 2 diabetes, patients using basal insulin, selected non-insulin-treated populations, primary-care-managed diabetes patients, Medicare beneficiaries, employer-sponsored populations, remote monitoring programs, and consumers purchasing OTC biosensors.

This broader market creates different design requirements. Type 1 diabetes users may prioritize highly automated insulin delivery, precision, interoperability, and safety. Type 2 users may place greater value on simplicity, medication optimization, meal-response insights, reduced finger-stick burden, and easy onboarding. Health systems require population dashboards and workflow integration. Payers require measurable evidence that device adoption reduces downstream expenditure.

The competitive implication is significant. The strongest companies will increasingly compete as data-and-device platforms, not simply as sensor or pump manufacturers. Hardware accuracy remains essential, but algorithm performance, interoperability, cloud analytics, user experience, automated decision support, cybersecurity, physician workflow, reimbursement access, and clinical evidence will increasingly determine market share.

Key Market Drivers: What’s Fueling the U.S. AI-Enabled Diabetes Care Devices Market Boom?

The largest underlying driver is the scale of diabetes in the United States. Approximately 12% of the U.S. population is estimated to have diabetes, with roughly 40.1 million people affected. An estimated 29.1 million have diagnosed disease, while approximately 11 million remain undiagnosed. The prediabetes population is substantially larger at more than 115 million adults. This creates a very large population in which glucose sensing and algorithm-enabled metabolic management can potentially expand.

A second driver is the transition from episodic measurement to continuous data generation. Traditional blood glucose meters provide isolated measurements. CGM systems generate persistent glucose trajectories, allowing algorithms to identify rate of change, recurrent patterns, overnight excursions, postprandial responses, and risk signals. The more complete data stream dramatically improves the usefulness of predictive analytics.

A third driver is automated insulin delivery. AI-enabled control algorithms can connect an integrated CGM with an insulin pump and dynamically modify insulin administration. The commercial significance expanded further when automated insulin dosing technology gained U.S. indications for adults with type 2 diabetes. This moves AID beyond a primarily type 1 diabetes opportunity and potentially opens access to a much larger insulin-requiring population.

A fourth driver is reimbursement. Medicare’s CGM eligibility framework no longer depends on the former requirement for multiple daily insulin administrations. Coverage is available for qualifying insulin-treated beneficiaries and certain patients with documented problematic hypoglycemia. This expands the economically addressable population and improves the ability of clinicians to prescribe connected monitoring technologies to older patients.

The fifth driver is consumerization. FDA clearance of over-the-counter glucose biosensors introduced a direct-access category for people not using insulin. Consumers can acquire biosensors without traditional specialist prescribing workflows. The commercial significance extends beyond immediate OTC revenue: consumer CGM expands familiarity with continuous glucose data and creates an entry point for AI-based nutrition, activity, metabolic, and risk-management applications.

A sixth driver is the increasing prevalence of device interoperability. Diabetes technology historically operated in proprietary silos. The market is increasingly moving toward architectures in which CGMs, insulin pumps, automated glycemic controllers, mobile applications, smart pens, and cloud platforms can communicate. Interoperability increases manufacturer partnership opportunities and gives users greater flexibility when configuring therapy.

A seventh driver is clinician capacity. Diabetes specialists face substantial volumes of CGM reports, pump downloads, patient messages, medication decisions, and longitudinal glucose information. AI can help prioritize patients with deteriorating control, identify recurrent hypoglycemia, summarize patterns, and reduce the amount of raw data clinicians must manually review. Systems that reduce rather than increase clinical workload are likely to receive stronger institutional support.

Finally, economics remain central. CDC burden estimates indicate that annual direct and indirect costs attributable to diabetes extend into hundreds of billions of dollars. This makes diabetes one of the clearest U.S. use cases for technology that can demonstrate measurable reductions in complications, emergency utilization, hospitalization, or clinician workload.

Innovation in Focus: How Manufacturers Are Raising the Bar?

The next innovation cycle is shifting from connected diabetes management toward adaptive diabetes management. Connectivity transfers information; adaptive intelligence changes treatment or recommendations based on that information. Manufacturers are therefore investing in algorithms capable of learning from patient-specific glucose patterns, insulin requirements, meals, and behavioral routines.

Automated insulin delivery remains the highest-acuity expression of this trend. Algorithms can review glucose readings continuously and adjust insulin at intervals impossible to reproduce manually throughout the day and night. Competition is increasingly centered on time in automated mode, target glucose flexibility, meal handling, correction logic, sensor choice, hypoglycemia protection, and reduced interaction burden.

The expansion of AID into type 2 diabetes is particularly important. Type 2 diabetes represents the overwhelming majority of U.S. diagnosed cases, but historically many advanced diabetes devices were designed around intensive type 1 management. New systems capable of accommodating broader insulin requirements and simpler patient workflows can materially enlarge the market.

CGM innovation is moving along several dimensions simultaneously. Sensor duration is increasing, device profiles are becoming smaller, calibration burden has declined, warm-up periods are improving, smartphone integration is standardizing, and connectivity with insulin delivery systems is expanding. The introduction of a 365-day implantable CGM provides a fundamentally different replacement model compared with short-duration disposable sensors.

Another innovation frontier is AI-assisted insulin dose optimization without full pump therapy. CGM-informed dose calculators and basal insulin optimization tools can analyze glucose patterns and recommend insulin adjustments. This could be particularly relevant to patients with type 2 diabetes who are not ready for pump therapy but still need assistance with insulin titration.

Meal intelligence is also developing. AI-enabled meal logging, image recognition, carbohydrate estimation, and post-meal glucose pattern analysis can reduce one of the major sources of diabetes-management friction. Rather than requiring precise manual food entry for every eating event, future platforms are likely to use simplified meal descriptions, image-based recognition, historical responses, and predictive models.

The competitive bar is also rising around interoperability. Abbott, Dexcom, Insulet, Tandem, MiniMed/Medtronic and other ecosystem participants are increasingly building or supporting multi-device connectivity. Partnerships between sensor and insulin-delivery manufacturers allow companies to preserve specialization while participating in larger therapy ecosystems.

Safety engineering remains a critical innovation requirement. AI in diabetes can influence insulin delivery, meaning software errors, data transmission failures, sensor inaccuracies, mobile-device settings, or missed alerts can have clinically serious consequences. The FDA has specifically highlighted risks associated with missed smartphone alerts from connected diabetes devices. Manufacturers therefore need redundant safety architecture, human-factors testing, secure communication, robust alarm handling, and post-market surveillance.

The long-term direction is toward increasingly autonomous systems, but complete autonomy will emerge incrementally. The near-term commercial winners are more likely to be technologies that remove several high-frequency patient decisions while retaining predictable safety controls than systems attempting to eliminate human oversight entirely.

Segmentation Insights

The U.S. AI-Enabled Diabetes Care Devices Market is segmented on the basis of product category, application, end user, technology type, and region.

By Product Category

AI-enabled continuous glucose monitoring systems represent the largest product category because CGM generates the real-time data required by many downstream diabetes algorithms. The category includes wearable integrated CGMs, longer-wear implantable systems, OTC biosensors, receivers, sensors, transmitters where applicable, and associated intelligent analytics. Abbott and Dexcom anchor the commercial scale of this category, while Senseonics provides differentiation through long-duration implantable monitoring. Replacement sensors create recurring revenue and make CGM economically attractive compared with one-time capital products.
Automated insulin delivery systems and smart insulin pumps represent the highest-value therapeutic segment. Products combine insulin pumps, CGMs, and automated control algorithms to modify insulin delivery based on glucose data. Omnipod 5, MiniMed 780G, Tandem systems using Control-IQ technology, iLet Bionic Pancreas and emerging interoperable systems are central to this segment. Expansion into type 2 diabetes materially increases the addressable population.
Connected insulin pens and intelligent dosing systems provide a bridge between conventional multiple daily injections and pump therapy. Smart pen components can capture dose information, provide reminders, calculate suggested doses, identify missed injections, and synchronize dosing information with glucose data. The segment is strategically important because many insulin-treated type 2 patients may prefer to remain on injections.
AI-enabled glucose meters and connected biosensors address users who do not require intensive CGM or pump therapy. Connected blood glucose meters can transmit readings into algorithms that identify patterns, provide personalized recommendations, and enable remote care programs. Although conventional BGM is mature, algorithm-connected systems can maintain relevance among cost-sensitive populations and patients using intermittent monitoring.
Device-linked diabetes intelligence platforms represent a smaller direct hardware revenue pool but an increasingly important source of differentiation. These platforms aggregate CGM, pump, connected meter, insulin, nutrition, activity, and medication information. Revenue can arise through software subscriptions, enterprise contracts, device bundles, remote monitoring programs, or embedded functionality. As physical devices become more interoperable, intelligence platforms may capture a larger portion of the lifetime value associated with diabetes management.

By Application

Automated insulin dosing and insulin optimization is expected to remain the largest high-value application. AI evaluates glucose information, insulin-on-board, historical responses, programmed parameters, and other inputs to adjust basal delivery or recommend doses. The shift toward type 2 indications considerably expands this application beyond its traditional intensive type 1 base.
Glucose prediction and intelligent alerting is a core application across CGM systems. Algorithms can identify likely high or low glucose trajectories before thresholds are reached, allowing users to intervene earlier. Predictive alerts are particularly valuable overnight, during exercise, and among patients with impaired hypoglycemia awareness.
Hypoglycemia prevention and safety management is a clinically important application because severe hypoglycemia can result in emergency care, hospitalization, loss of consciousness, injury, or death. AI-enabled systems can suspend or reduce insulin, generate predictive alerts, and identify recurrent risk patterns.
Personalized lifestyle and meal-response management is emerging rapidly as CGM expands outside intensive insulin therapy. Algorithms can relate meals, physical activity, sleep, and daily routines to glucose responses. OTC glucose biosensors will strengthen this segment because users may enter through metabolic awareness rather than conventional diabetes-device pathways.
Remote monitoring and population risk stratification represents a major institutional opportunity. Diabetes clinics, primary-care organizations, payers, employers, and digital-care providers can use algorithmic prioritization to identify patients with persistent hyperglycemia, recurrent hypoglycemia, declining sensor use, or other indicators requiring intervention. This can convert device data into scalable chronic-disease management.

By End User

Hospitals and integrated health systems are strategically important users because they manage complex diabetes populations, inpatient-to-outpatient transitions, endocrinology programs, and enterprise digital infrastructure. Health systems increasingly evaluate diabetes technologies through clinical outcomes, workflow impact, cybersecurity, interoperability, and total cost of care rather than device price alone.
Endocrinology and diabetes specialty centers remain the most influential early-adopter segment. These providers manage patients requiring pumps, AID, advanced CGM interpretation, intensive insulin adjustment, and complex hypoglycemia management. They also influence device choice through prescribing patterns, clinical studies, professional education, and patient training.
Primary-care practices represent one of the largest future growth opportunities. Most Americans with type 2 diabetes are not managed exclusively by endocrinologists. Devices that simplify prescribing, onboarding, data interpretation, and treatment adjustment can move sophisticated diabetes management into primary care and dramatically increase market penetration.
Home users and patients constitute the economic center of the market because diabetes care is predominantly longitudinal and self-managed. Wearability, sensor duration, mobile user experience, alarm burden, automated decision-making, out-of-pocket cost, pharmacy availability, and device simplicity directly affect persistence.
Remote patient monitoring and digital health providers are becoming important channels for device-enabled diabetes management. Their business models depend on continuous data, scalable clinical workflows, algorithmic patient prioritization, and measurable engagement. Device manufacturers that expose usable APIs or interoperable data architectures may gain distribution through these platforms.

By Technology Type

Machine learning and predictive analytics form the broadest AI technology segment. These approaches identify glucose patterns, forecast excursions, estimate risks, classify patient behavior, and personalize recommendations. Their importance increases with the quantity and continuity of CGM data.
Adaptive control and closed-loop algorithms generate the highest therapeutic value because they can directly influence insulin administration. Control systems repeatedly compare actual glucose information against therapeutic objectives and alter insulin delivery accordingly.
Computer vision and intelligent meal recognition represent an emerging technology area. Image-based meal identification and simplified food logging can reduce the manual burden associated with carbohydrate estimation. Commercial success will depend on accuracy, cultural food coverage, usability, and integration with glucose and insulin data.
Cloud AI and population analytics support clinician and payer use cases. Rather than analyzing only one patient’s glucose curve, cloud systems can evaluate thousands of users, prioritize intervention, identify utilization patterns, and support quality measurement. This is particularly relevant for integrated delivery networks and value-based care.
Edge intelligence and sensor fusion are expected to gain importance as devices process more information locally. Combining glucose values with insulin history, wearable activity data, meals, heart rate, sleep or other signals may allow systems to make faster and more contextual decisions while reducing dependence on continuous cloud connectivity.

Regional Insights: Where the Market is Growing Fastest

The U.S. AI-Enabled Diabetes Care Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional adoption varies according to diabetes prevalence, population size, Medicare exposure, health-system sophistication, specialist availability, commercial insurance penetration, pharmacy distribution, digital-health adoption, income levels, and proximity to diabetes technology development ecosystems.

In 2025, the South represents an estimated USD 2.28 billion, the West approximately USD 2.05 billion, the Northeast USD 1.62 billion, and the Midwest USD 1.30 billion. The South is the largest current market because of population and diabetes burden, while the West is projected to grow fastest because of digital-health intensity, technology adoption and the presence of major diabetes-device companies. By 2035, regional values are projected at approximately USD 11.38 billion for the South, USD 11.70 billion for the West, USD 7.45 billion for the Northeast, and USD 5.09 billion for the Midwest.

South

The South is the largest current regional market and accounts for approximately 31.4% of 2025 U.S. revenue. It includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, Maryland, Delaware, West Virginia, Kentucky, Tennessee, Alabama, Mississippi, Louisiana, Arkansas and Oklahoma, with Washington, D.C. commercially linked to the Mid-Atlantic provider ecosystem.

The region combines a disproportionately high diabetes burden with several of the country’s fastest-growing metropolitan populations. CDC surveillance consistently identifies Southern states among those with the highest diagnosed diabetes prevalence. Louisiana has reported adult diagnosed diabetes prevalence around 14.5%, Alabama approximately 13.7%, Arkansas approximately 13.0%, Kentucky about 12.9%, and Georgia around 11.4% in recent surveillance data.

Texas is the most important commercial opportunity in the region because of its scale, large insured population, extensive pharmacy networks, major endocrinology markets and health-system concentration in Houston, Dallas-Fort Worth, Austin and San Antonio. East Texas carries particularly high diabetes prevalence, reinforcing the opportunity for lower-burden CGM, remote monitoring and primary-care-oriented diabetes technologies.

Florida is critical because of its large Medicare population and older demographic profile. AI-enabled CGMs and intelligent dosing systems are well aligned with older insulin-treated patients who require simplified interfaces and remote caregiver visibility. Pharmacy-channel access and Medicare reimbursement are especially important competitive levers.

North Carolina, Georgia, Virginia, Tennessee and Maryland combine significant diabetes populations with expanding health systems and research infrastructure. North Carolina’s Research Triangle and major academic systems can support clinical evaluation and digital-health deployment, while Maryland and Virginia benefit from sophisticated provider networks and proximity to federal health institutions.

Mississippi, Alabama, Louisiana, Arkansas, Kentucky, Oklahoma and West Virginia offer substantial unmet clinical need but create more complex commercial economics because rurality, affordability constraints, clinician shortages and uneven specialist access can slow premium-device penetration. AI-enabled solutions that simplify management for primary care, support remote monitoring and reduce the need for frequent specialist visits may be especially valuable.

The South is forecast to expand from USD 2.28 billion in 2025 to approximately USD 11.38 billion by 2035, equivalent to an estimated CAGR of approximately 17.44%. Its long-term opportunity will depend on how effectively manufacturers convert high disease burden into sustained device access rather than limiting adoption to wealthy metropolitan markets.

West

The West is expected to be the fastest-growing U.S. region, increasing from approximately USD 2.05 billion in 2025 to USD 11.70 billion by 2035, representing an estimated CAGR of 19.03%.

The region includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii. Its growth profile is driven less by uniformly high diabetes prevalence and more by technological readiness, venture activity, connected-care adoption, employer-sponsored health innovation and the presence of major diabetes technology companies.

California is the strategic center of the U.S. diabetes-device innovation ecosystem. Dexcom is headquartered in San Diego, Tandem Diabetes Care is also based in the San Diego area, and Abbott Diabetes Care has major operations in California. The state therefore combines product development, engineering talent, clinical research, venture financing and a very large patient population. California’s adult diagnosed diabetes prevalence is approximately 10.5% in recent CDC surveillance, meaning even a moderate prevalence rate translates into a substantial absolute patient pool because of the state’s population scale.

Arizona and Nevada are high-growth commercial markets due to population migration and aging. Both are attractive for CGM, insulin automation, Medicare-oriented diabetes management and home monitoring. Colorado and Utah have comparatively lower diabetes prevalence but strong digital-health adoption, integrated health systems and populations receptive to wearable technology.

Washington and Oregon are important markets for connected diabetes management, remote monitoring and value-oriented health-system procurement. Their provider ecosystems are well suited to platforms capable of integrating CGM data into longitudinal chronic-disease workflows.

New Mexico carries a different opportunity profile, with meaningful diabetes burden and access challenges that increase the clinical relevance of remote management. Idaho, Montana, Wyoming and Alaska are smaller device markets but have geographically dispersed populations, making virtual diabetes care and remote data access particularly useful. Hawaii is comparatively small in revenue but benefits from strong health-system concentration and clear utility for remotely connected chronic-care models.

The West is expected to overtake the South in total market value by 2035 under the report’s aggressive adoption scenario. The principal growth engine will be the commercialization of AI functionality beyond insulin automation into OTC biosensors, personalized metabolic intelligence, population analytics and primary-care decision support.

Northeast

The Northeast represented approximately USD 1.62 billion in 2025 and is projected to reach USD 7.45 billion by 2035, producing an estimated 16.48% CAGR.

The region includes New York, New Jersey, Pennsylvania, Massachusetts, Connecticut, Rhode Island, Vermont, New Hampshire and Maine, with Delaware sometimes grouped into the Mid-Atlantic commercial market. Its competitive advantage is the density of academic medical centers, endocrinologists, research institutions, payer headquarters and sophisticated integrated delivery networks.

New York is the largest Northeast state opportunity because of its population, large Medicaid and Medicare populations, substantial commercial insurance market, extensive specialist networks and major health systems. AI-enabled devices that can demonstrate improvements in high-risk populations and reduce clinical workload have strong relevance in large urban diabetes programs.

Massachusetts is disproportionately influential because of its concentration of academic research and digital-health companies. Although its absolute diabetes-device market is smaller than New York or Pennsylvania, adoption decisions at major Boston institutions can influence clinical evidence generation and broader U.S. technology acceptance.

Pennsylvania and New Jersey provide large mixed populations spanning academic centers, suburban commercially insured markets, Medicare beneficiaries and lower-income urban populations. The states are attractive for CGM expansion and device-enabled population management because they combine scale with mature health-system infrastructure.

Connecticut, Rhode Island, New Hampshire, Vermont and Maine are smaller markets but provide opportunities in integrated care, older populations and remotely managed diabetes. Rural portions of Maine, Vermont and New Hampshire strengthen the value proposition for technologies that reduce travel and allow centralized specialist supervision.

The Northeast is unlikely to match the West’s growth rate because diabetes technology adoption is already comparatively mature in several premium provider systems. However, revenue per treated patient can remain attractive because of strong commercial reimbursement, advanced clinical programs and willingness to adopt evidence-supported technologies.

Midwest

The Midwest accounted for approximately USD 1.30 billion in 2025 and is projected to reach about USD 5.09 billion by 2035, representing a CAGR of approximately 14.62%.

The region includes Illinois, Ohio, Michigan, Indiana, Wisconsin, Minnesota, Missouri, Iowa, Kansas, Nebraska, North Dakota and South Dakota.

Illinois represents the largest commercial market in the region, supported by Chicago’s large provider ecosystem and a recent adult diagnosed diabetes prevalence around 10.8%. Indiana has a comparatively high diabetes burden at approximately 11.5%, strengthening demand for CGM and simplified insulin-management technologies.

Ohio and Michigan have large populations, substantial chronic disease burden and major integrated health systems, making them important markets for both traditional diabetes-device distribution and AI-supported population management. Minnesota has particular strategic importance because of its long-established medical-device ecosystem and sophisticated provider organizations.

Wisconsin, Missouri, Iowa and Kansas offer stable demand through community health systems, endocrinology networks and pharmacy distribution. Nebraska, North Dakota and South Dakota represent smaller revenue markets but highlight the value of remote endocrinology and connected patient monitoring because substantial portions of their populations live far from major specialty centers.

The Midwest is expected to grow more slowly than the West, South and Northeast because of slower population growth and greater price sensitivity in several markets. Manufacturers can nevertheless build durable share by emphasizing reimbursement navigation, clinical training, pharmacy availability, sensor affordability, dependable customer service and integration with large regional health systems.

Key Market Players

The competitive landscape is concentrated among a small number of high-scale CGM and insulin-delivery companies at the top, surrounded by emerging automated insulin delivery developers, implantable sensor companies, connected-device manufacturers and diabetes intelligence platforms.

Some of the key companies relevant to the U.S. AI-enabled diabetes care devices ecosystem include Abbott Diabetes Care, Dexcom, Insulet Corporation, MiniMed/Medtronic Diabetes, Tandem Diabetes Care, Beta Bionics, Senseonics Holdings, Ascensia Diabetes Care, Sequel Med Tech, Roche Diabetes Care, LifeScan, embecta, AgaMatrix, Glooko, Welldoc, DarioHealth, Teladoc Health/Livongo, Omada Health, Tidepool, i-SENS, Trividia Health, Novo Nordisk’s connected insulin-device ecosystem and selected digital diabetes platform developers integrating with CGM and insulin-delivery systems.

Abbott and Dexcom hold particularly strong positions in the glucose-sensing layer. Their scale matters because CGM data increasingly becomes the input for automated dosing and personalized decision support. Abbott has built FreeStyle Libre into a multibillion-dollar global franchise with millions of users, while Dexcom generated approximately USD 4.66 billion in worldwide revenue during 2025 and recorded double-digit U.S. growth.

Insulet is one of the most important AI-enabled insulin delivery competitors through Omnipod 5. The company generated approximately USD 1.9 billion of U.S. Omnipod revenue in 2025, growing more than 27% year over year, and ended the year with an estimated global customer base exceeding 600,000 users.

MiniMed/Medtronic remains strategically important through the MiniMed 780G ecosystem and algorithm-driven insulin automation. The planned separation of Medtronic’s Diabetes business under the MiniMed identity demonstrates the strategic value of establishing a more focused diabetes technology company.

Tandem Diabetes Care competes through interoperable insulin pumps and Control-IQ technology. FDA clearance of Control-IQ+ for adults with type 2 diabetes in 2025 illustrates how leading AID manufacturers are moving beyond the historical type 1 market.

Beta Bionics differentiates through the iLet Bionic Pancreas and simplified automated dosing philosophy. Senseonics and Ascensia offer differentiation in implantable CGM through Eversense 365. Sequel Med Tech introduces additional competitive pressure in automated insulin delivery through its twiist platform.

Competition over the next decade will increasingly center on five assets: access to high-quality continuous data, algorithm performance, installed patient base, payer coverage and ecosystem interoperability. Companies owning only one hardware component will need partnerships or differentiated intellectual property to prevent commoditization.

Recent Developments

Recent U.S. developments demonstrate how quickly the diabetes-device market is moving from connected measurement toward algorithmic treatment.

In March 2024, the FDA cleared Dexcom’s Stelo as the first over-the-counter CGM for adults not using insulin. The decision established a new commercial category in which glucose biosensors could reach people outside conventional prescription-based intensive diabetes management.

In May and June 2024, Abbott’s Lingo and Libre Rio systems received U.S. clearances, expanding the OTC glucose-sensing landscape and creating additional competition around non-insulin glucose monitoring and metabolic data.

In August 2024, the FDA expanded Insulet’s SmartAdjust automated glycemic controller technology for use in adults with type 2 diabetes. The regulatory decision was supported by a study involving 289 adults with type 2 diabetes using insulin and marked an important expansion of automated insulin delivery beyond the traditional type 1 population.

In September 2024, Eversense 365 received U.S. clearance, establishing the first integrated CGM designed around a single sensor lasting up to one year. The product changes the conventional short-duration sensor replacement model and gives Senseonics and Ascensia a distinct position in long-wear glucose monitoring.

During 2025, Tandem received U.S. clearance for Control-IQ+ for adults with type 2 diabetes, further validating type 2 diabetes as the next major competitive frontier for automated insulin delivery.

Medtronic also advanced its U.S. ecosystem during 2025 through Simplera Sync integration with MiniMed 780G and later commercialization of the MiniMed 780G system with Abbott’s Instinct sensor. The development demonstrates a broader industry shift toward sensor choice and partnership-based interoperability.

Dexcom launched the G7 15 Day system in the U.S. during 2025 and received FDA clearance for Dexcom Smart Basal, a CGM-informed basal insulin dose optimization technology. This development is strategically important because it represents algorithmic insulin decision support without necessarily requiring complete pump-based automated insulin delivery.

Competitive restructuring also accelerated. Medtronic announced plans during 2025 to separate its Diabetes business into a standalone company under the MiniMed name, indicating that diabetes technology is increasingly viewed as a specialized, innovation-intensive market requiring dedicated capital allocation and operating focus.

Conclusion

The U.S. AI-Enabled Diabetes Care Devices Market Size & Share is positioned to increase from approximately USD 7.25 billion in 2025 to USD 35.62 billion by 2035, supported by an estimated 17.26% CAGR during 2026–2035.

The central growth driver is not AI in isolation. It is the convergence of AI with high-frequency glucose sensing, connected insulin delivery, expanding reimbursement, interoperable medical devices, cloud infrastructure and a U.S. diabetes population exceeding 40 million people.

Continuous glucose monitoring will remain the data foundation of the market, while automated insulin delivery will generate some of the highest-value therapeutic opportunities. The next expansion layer will come from type 2 diabetes, particularly insulin-treated adults who historically had limited access to automated technologies. Longer term, non-insulin users and metabolic-health consumers will enlarge the market further through OTC biosensors and personalized analytics.

For manufacturers, the most attractive opportunities will be AI-enabled CGM, type 2 automated insulin delivery, CGM-informed basal insulin optimization, predictive hypoglycemia management, intelligent meal-response tools, long-duration sensing, interoperable pump-CGM ecosystems and population-level diabetes analytics.

For U.S. health systems and payers, procurement decisions will increasingly depend on measurable outcomes rather than technical sophistication alone. A device that generates more information but adds clinical workload may have limited economic value. A platform that improves glycemic control while automating routine decisions, prioritizing high-risk patients and reducing acute utilization will have a stronger value proposition.

Regionally, the South will remain a major revenue center because of its population and disproportionate diabetes burden, while the West is projected to deliver the fastest expansion because of its technology ecosystem and adoption of digitally enabled care. California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, North Carolina, Georgia, Massachusetts, Arizona, Michigan and New Jersey represent particularly important commercial markets, while high-burden rural states create an additional opportunity for simplified and remotely managed diabetes technology.

The competitive landscape will increasingly shift from individual devices toward integrated ecosystems. Abbott, Dexcom, Insulet, MiniMed, Tandem and other leading companies are already competing across sensors, algorithms, insulin delivery, interoperability, patient interfaces and clinical data. Smaller innovators can still gain share when they solve clearly defined problems such as long-duration monitoring, simplified automation, insulin titration or data interpretation.

By 2035, the most valuable diabetes technologies are unlikely to be defined simply by whether they measure glucose or deliver insulin. Market leadership will increasingly belong to platforms capable of sensing patient physiology continuously, interpreting the information intelligently, predicting risk before it occurs and initiating or recommending the appropriate response with minimal patient burden. That transition from reactive diabetes management to predictive and adaptive care defines the long-term investment case for the U.S. AI-Enabled Diabetes Care Devices Market.

TABLE OF CONTENT

1. U.S. AI-Enabled Diabetes Care Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. AI-Enabled Medical Device Market Sizing Framework
1.3.6. Analytical Frameworks & Forecasting Models
1.3.7. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Continuous Glucose Monitoring Manufacturers
1.6.2. Automated Insulin Delivery and Insulin Pump Manufacturers
1.6.3. Connected Insulin Pen and Intelligent Dosing Device Companies
1.6.4. AI, Algorithm and Diabetes Data Platform Developers
1.6.5. Hospitals and Integrated Health Systems
1.6.6. Endocrinology and Diabetes Specialty Practices
1.6.7. Primary Care Organizations
1.6.8. Retail Pharmacies and Durable Medical Equipment Suppliers
1.6.9. Commercial Payers, Medicare and Medicaid
1.6.10. Patients, Caregivers and Remote Monitoring Providers
1.6.11. FDA, CMS and Clinical Decision-Makers

What this section provides: This section establishes the market boundary, device and AI inclusion criteria, methodology, assumptions, value-chain participants and stakeholder ecosystem used to measure and validate the U.S. AI-enabled diabetes care devices market.

2. U.S. AI-Enabled Diabetes Care Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size & Growth Snapshot, 2021–2035
2.8. High-Growth Opportunity Areas
2.8.1. AI-Enabled Continuous Glucose Monitoring
2.8.2. Automated Insulin Delivery
2.8.3. Type 2 Diabetes AID Expansion
2.8.4. Predictive Hypoglycemia Management
2.8.5. Intelligent Insulin Dose Optimization
2.8.6. OTC Glucose Biosensors and AI-Driven Metabolic Intelligence
2.8.7. Remote Diabetes Monitoring and Population Analytics

What this section provides: This section gives decision-makers a concise view of market size, CAGR, historical performance, forecast direction, adoption trends, competitive intensity and the highest-priority AI-enabled diabetes device opportunities through 2035.

3. U.S. AI-Enabled Diabetes Care Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Diabetes and Prediabetes Burden
3.1.2. Rapid Adoption of Continuous Glucose Monitoring
3.1.3. Expansion of Automated Insulin Delivery Systems
3.1.4. Growing Adoption of AI-Enabled Diabetes Management
3.1.5. Increasing Type 2 Diabetes Eligibility for Advanced Devices
3.1.6. Expansion of Medicare and Commercial CGM Coverage
3.1.7. Growing Demand for Personalized and Predictive Diabetes Care
3.1.8. Increasing Remote Patient Monitoring Adoption
3.1.9. Shift from Finger-Stick Monitoring toward Continuous Data
3.1.10. Growing Consumer Acceptance of Wearable Health Technologies
3.2. Restraints and Their Impact Analysis
3.2.1. High Upfront and Recurring Device Costs
3.2.2. Insurance Coverage and Prior Authorization Complexity
3.2.3. Patient Affordability and Out-of-Pocket Burden
3.2.4. Alarm Fatigue and Device Adherence Challenges
3.2.5. Data Privacy and Cybersecurity Concerns
3.2.6. AI Algorithm Transparency and Clinical Trust Issues
3.2.7. Smartphone and Digital Literacy Barriers
3.3. Opportunities and Their Impact Analysis
3.3.1. AI-Enabled AID Expansion into Type 2 Diabetes
3.3.2. OTC Continuous Glucose Biosensor Adoption
3.3.3. CGM-Informed Basal Insulin Optimization
3.3.4. Predictive Hypoglycemia Prevention
3.3.5. AI-Based Meal Recognition and Nutritional Guidance
3.3.6. Primary Care Expansion of Advanced Diabetes Technology
3.3.7. AI-Enabled Remote Diabetes Management
3.3.8. Longer-Wear and Implantable CGM Systems
3.3.9. Interoperable CGM-Pump-Software Ecosystems
3.3.10. Employer and Value-Based Diabetes Management Programs
3.4. Challenges and Their Impact Analysis
3.4.1. Algorithm Validation Across Diverse Patient Populations
3.4.2. Interoperability Between CGMs, Pumps and Apps
3.4.3. Clinical Workflow Integration
3.4.4. AI-Related Regulatory Complexity
3.4.5. Device Connectivity and Smartphone Reliability
3.4.6. Patient Training and Long-Term Engagement
3.5. Patent & Innovation Analysis, 2021–2025
3.6. AI Algorithm Innovation and Intellectual Property Landscape
3.7. Clinical Workflow Economics Analysis
3.8. Diabetes Technology Adoption Economics
3.9. Health System and Payer Value Proposition Analysis
3.10. Patient Lifetime Device Economics

What this section provides: This section explains the clinical, technological, reimbursement, behavioral and economic forces influencing AI-enabled diabetes device adoption and helps clients evaluate growth catalysts, market-entry opportunities and execution risks.

4. U.S. AI-Enabled Diabetes Care Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.4.1. Sensor and Semiconductor Suppliers
4.4.2. Glucose Biosensor Manufacturers
4.4.3. Insulin Pump and Delivery Platform Manufacturers
4.4.4. Algorithm and Software Developers
4.4.5. Cloud and Connectivity Infrastructure
4.4.6. Pharmacy and DME Distribution
4.4.7. Providers and Diabetes Care Teams
4.4.8. End Patients
4.5. Impact of Digitalization and Connected Diabetes Care
4.6. AI & Machine Learning Application Landscape
4.7. Device Interoperability Landscape
4.8. FDA Regulatory Framework Analysis
4.8.1. Continuous Glucose Monitoring Devices
4.8.2. Automated Insulin Delivery Systems
4.8.3. Automated Glycemic Controllers
4.8.4. Integrated CGM Systems
4.8.5. Interoperable Insulin Pumps
4.8.6. AI/ML-Enabled Medical Device Software
4.9. CMS Reimbursement and Coverage Landscape
4.10. Medicare CGM Coverage Evolution
4.11. Commercial Payer Coverage and Prior Authorization Trends
4.12. Cybersecurity, Data Privacy and Connected Device Risk
4.13. Import/Export Restrictions & Tariff Impact
4.14. Government Diabetes Prevention and Chronic Care Initiatives
4.15. Impact of Semiconductor and Biosensor Supply Constraints
4.16. Impact of Escalating Geopolitical Tensions
4.17. Health System Technology Assessment and Value Analysis Framework

What this section provides: This section gives clients a comprehensive view of regulation, reimbursement, AI governance, pricing, interoperability, cybersecurity, value chains, supply risks and external forces affecting commercialization of AI-enabled diabetes care devices.

5. U.S. AI-Enabled Diabetes Care Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. AI-Enabled Continuous Glucose Monitoring Systems
5.1.2.1. Wearable CGM Systems
5.1.2.2. Integrated CGM Systems
5.1.2.3. Long-Wear and Implantable CGM Systems
5.1.2.4. OTC Glucose Biosensors
5.1.2.5. Predictive CGM Analytics Platforms
5.1.3. Automated Insulin Delivery Systems & Smart Insulin Pumps
5.1.3.1. Tubeless AID Systems
5.1.3.2. Tubed AID Systems
5.1.3.3. Hybrid Closed-Loop Systems
5.1.3.4. Adaptive Insulin Delivery Systems
5.1.3.5. Bionic and Highly Automated Insulin Delivery Systems
5.1.4. Connected Insulin Pens & Intelligent Dosing Systems
5.1.4.1. Smart Reusable Insulin Pens
5.1.4.2. Connected Pen Caps and Attachments
5.1.4.3. CGM-Integrated Dose Calculators
5.1.4.4. Basal Insulin Optimization Systems
5.1.4.5. Injection Tracking and Adherence Systems
5.1.5. AI-Enabled Glucose Meters & Connected Biosensors
5.1.5.1. Connected Blood Glucose Meters
5.1.5.2. Pattern Recognition Glucose Monitoring Systems
5.1.5.3. Cloud-Connected Glucose Monitoring Devices
5.1.5.4. Multi-Parameter Metabolic Biosensors
5.1.6. Device-Linked Diabetes Intelligence Platforms
5.1.6.1. Predictive Analytics Platforms
5.1.6.2. Insulin Decision-Support Platforms
5.1.6.3. Patient Coaching and Personalized Guidance Platforms
5.1.6.4. Clinical Diabetes Data Management Platforms
5.1.6.5. Population-Level Diabetes Analytics Platforms

What this section provides: This section identifies which AI-enabled diabetes device product categories are expected to generate the highest revenue contribution, recurring revenue potential and strongest growth through 2035.

6. U.S. AI-Enabled Diabetes Care Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Automated Insulin Dosing & Insulin Optimization
6.1.2.1. Automated Basal Adjustment
6.1.2.2. Automated Correction Dosing
6.1.2.3. Meal-Time Insulin Optimization
6.1.2.4. Basal Insulin Titration
6.1.2.5. Personalized Insulin Requirement Prediction
6.1.3. Glucose Prediction & Intelligent Alerting
6.1.3.1. Predictive Low-Glucose Alerts
6.1.3.2. Predictive Hyperglycemia Alerts
6.1.3.3. Rate-of-Change Prediction
6.1.3.4. Overnight Glucose Risk Prediction
6.1.3.5. Personalized Glucose Pattern Detection
6.1.4. Hypoglycemia Prevention & Safety Management
6.1.4.1. Predictive Insulin Suspension
6.1.4.2. Automated Insulin Reduction
6.1.4.3. Severe Hypoglycemia Risk Identification
6.1.4.4. Caregiver Alerts and Remote Safety Monitoring
6.1.5. Personalized Lifestyle & Meal-Response Management
6.1.5.1. AI-Based Meal Recognition
6.1.5.2. Carbohydrate Estimation
6.1.5.3. Personalized Food-Response Analytics
6.1.5.4. Exercise and Activity Response Prediction
6.1.5.5. Metabolic Pattern Analytics
6.1.6. Remote Monitoring & Population Risk Stratification
6.1.6.1. Remote Patient Monitoring
6.1.6.2. High-Risk Patient Identification
6.1.6.3. Clinical Workflow Prioritization
6.1.6.4. Population Glycemic Management
6.1.6.5. Value-Based Diabetes Management

What this section provides: This section evaluates AI-enabled diabetes device demand by clinical use case and identifies applications with the strongest potential to improve glycemic outcomes, reduce patient burden and support lower-cost longitudinal diabetes management.

7. U.S. AI-Enabled Diabetes Care Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Hospitals & Integrated Health Systems
7.1.2.1. Academic Medical Centers
7.1.2.2. Integrated Delivery Networks
7.1.2.3. Community Hospital Systems
7.1.2.4. Hospital-Based Diabetes Programs
7.1.3. Endocrinology & Diabetes Specialty Centers
7.1.3.1. Endocrinology Practices
7.1.3.2. Diabetes Technology Clinics
7.1.3.3. Pediatric Diabetes Centers
7.1.3.4. Academic Diabetes Programs
7.1.4. Primary Care Practices
7.1.4.1. Independent Primary Care Practices
7.1.4.2. Health System-Affiliated Primary Care Networks
7.1.4.3. Federally Qualified Health Centers
7.1.4.4. Value-Based Primary Care Organizations
7.1.5. Home Users & Patients
7.1.5.1. Type 1 Diabetes Patients
7.1.5.2. Insulin-Treated Type 2 Diabetes Patients
7.1.5.3. Non-Insulin-Treated Type 2 Diabetes Users
7.1.5.4. Prediabetes and Metabolic Health Users
7.1.5.5. Medicare-Age Diabetes Patients
7.1.6. Remote Patient Monitoring & Digital Health Providers
7.1.6.1. Virtual Diabetes Clinics
7.1.6.2. Chronic Care Management Providers
7.1.6.3. Employer-Sponsored Diabetes Management Programs
7.1.6.4. Payer-Sponsored Digital Diabetes Programs

What this section provides: This section explains which U.S. care settings and patient groups will drive prescription volume, device utilization, recurring sensor demand and adoption of AI-supported diabetes management technologies.

8. U.S. AI-Enabled Diabetes Care Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Machine Learning & Predictive Analytics
8.1.2.1. Glucose Forecasting Algorithms
8.1.2.2. Pattern Recognition Algorithms
8.1.2.3. Personalized Risk Prediction
8.1.2.4. Insulin Requirement Prediction
8.1.2.5. Behavioral Pattern Analytics
8.1.3. Adaptive Control & Closed-Loop Algorithms
8.1.3.1. Model Predictive Control
8.1.3.2. Adaptive Insulin Control Algorithms
8.1.3.3. Automated Glycemic Controllers
8.1.3.4. Hybrid Closed-Loop Algorithms
8.1.3.5. Highly Automated Insulin Delivery Algorithms
8.1.4. Computer Vision & Intelligent Meal Recognition
8.1.4.1. Food Image Recognition
8.1.4.2. Carbohydrate Estimation
8.1.4.3. Portion Estimation
8.1.4.4. Meal-Response Prediction
8.1.5. Cloud AI & Population Analytics
8.1.5.1. Clinical Decision-Support Analytics
8.1.5.2. Population Health Analytics
8.1.5.3. Remote Monitoring Prioritization
8.1.5.4. Cloud-Based Diabetes Data Aggregation
8.1.6. Edge Intelligence & Sensor Fusion
8.1.6.1. On-Device AI Processing
8.1.6.2. CGM and Insulin Data Fusion
8.1.6.3. Activity and Wearable Data Integration
8.1.6.4. Multi-Sensor Metabolic Intelligence
8.1.6.5. Context-Aware Diabetes Algorithms

What this section provides: This section assesses the AI and algorithm technologies shaping diabetes care and identifies which predictive, adaptive, cloud, computer-vision and sensor-fusion architectures are expected to drive future device differentiation.

9. U.S. AI-Enabled Diabetes Care Devices Market: Market Access, Reimbursement & Procurement Pathways

9.1. U.S. Market Access Overview
9.2. Medicare Coverage Pathways
9.2.1. CGM Coverage
9.2.2. Insulin Pump Coverage
9.2.3. Automated Insulin Delivery Coverage Considerations
9.2.4. Durable Medical Equipment Benefit
9.2.5. Pharmacy Benefit Access
9.3. Medicaid Coverage Landscape
9.4. Commercial Insurance Coverage Landscape
9.5. Pharmacy Benefit vs. DME Benefit Economics
9.6. Prior Authorization and Documentation Requirements
9.7. Retail Pharmacy Distribution Model
9.8. Durable Medical Equipment Distribution Model
9.9. Direct-to-Patient Manufacturer Fulfillment
9.10. Hospital and Health System Technology Procurement
9.11. Endocrinology Practice Prescribing Dynamics
9.12. Primary Care Adoption and Prescribing Barriers
9.13. Employer and Health Plan Contracting
9.14. Digital Diabetes Program Partnerships
9.15. OTC Glucose Biosensor Commercialization Pathway
9.16. Patient Co-Pay and Affordability Analysis
9.17. Reimbursement Risk Assessment, 2026–2035

What this section provides: This section explains how AI-enabled diabetes devices reach U.S. patients through Medicare, Medicaid, commercial insurance, pharmacy, DME, provider, employer and direct-consumer channels without introducing an additional formal market segmentation.

10. U.S. AI-Enabled Diabetes Care Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Diabetes Prevalence and Addressable Patient Analysis
10.1.4. Regional CGM and AID Adoption Analysis
10.1.5. Regional Medicare and Commercial Payer Dynamics
10.1.6. Regional Endocrinology and Diabetes Care Infrastructure
10.1.7. Regional Digital Health and AI Adoption Readiness
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region Key Manufacturers, Clinical Centers and Commercial Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. California
10.2.8.1. Overview
10.2.8.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.8.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.8.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.8.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9. Washington
10.2.9.1. Overview
10.2.9.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10. Arizona
10.2.10.1. Overview
10.2.10.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11. Colorado
10.2.11.1. Overview
10.2.11.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12. Oregon
10.2.12.1. Overview
10.2.12.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13. Utah
10.2.13.1. Overview
10.2.13.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14. Nevada
10.2.14.1. Overview
10.2.14.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15. New Mexico
10.2.15.1. Overview
10.2.15.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16. Idaho
10.2.16.1. Overview
10.2.16.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17. Montana
10.2.17.1. Overview
10.2.17.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18. Wyoming
10.2.18.1. Overview
10.2.18.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19. Alaska
10.2.19.1. Overview
10.2.19.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20. Hawaii
10.2.20.1. Overview
10.2.20.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Key Manufacturers, Clinical Centers and Commercial Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. New York
10.3.8.1. Overview
10.3.8.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.8.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.8.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.8.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9. Massachusetts
10.3.9.1. Overview
10.3.9.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10. New Jersey
10.3.10.1. Overview
10.3.10.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11. Pennsylvania
10.3.11.1. Overview
10.3.11.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12. Connecticut
10.3.12.1. Overview
10.3.12.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13. Maine
10.3.13.1. Overview
10.3.13.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14. Vermont
10.3.14.1. Overview
10.3.14.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15. New Hampshire
10.3.15.1. Overview
10.3.15.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16. Rhode Island
10.3.16.1. Overview
10.3.16.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17. Delaware
10.3.17.1. Overview
10.3.17.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region Key Manufacturers, Clinical Centers and Commercial Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. Texas
10.4.8.1. Overview
10.4.8.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.8.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.8.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.8.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9. Florida
10.4.9.1. Overview
10.4.9.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10. Georgia
10.4.10.1. Overview
10.4.10.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11. North Carolina
10.4.11.1. Overview
10.4.11.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12. Tennessee
10.4.12.1. Overview
10.4.12.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13. South Carolina
10.4.13.1. Overview
10.4.13.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14. Alabama
10.4.14.1. Overview
10.4.14.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15. Mississippi
10.4.15.1. Overview
10.4.15.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16. Louisiana
10.4.16.1. Overview
10.4.16.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17. Arkansas
10.4.17.1. Overview
10.4.17.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18. Kentucky
10.4.18.1. Overview
10.4.18.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19. Oklahoma
10.4.19.1. Overview
10.4.19.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20. Virginia
10.4.20.1. Overview
10.4.20.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21. Maryland
10.4.21.1. Overview
10.4.21.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22. West Virginia
10.4.22.1. Overview
10.4.22.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Key Manufacturers, Clinical Centers and Commercial Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Illinois
10.5.8.1. Overview
10.5.8.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.8.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.8.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.8.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9. Ohio
10.5.9.1. Overview
10.5.9.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10. Michigan
10.5.10.1. Overview
10.5.10.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11. Minnesota
10.5.11.1. Overview
10.5.11.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12. Indiana
10.5.12.1. Overview
10.5.12.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13. Wisconsin
10.5.13.1. Overview
10.5.13.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14. Missouri
10.5.14.1. Overview
10.5.14.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15. Iowa
10.5.15.1. Overview
10.5.15.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16. Kansas
10.5.16.1. Overview
10.5.16.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17. Nebraska
10.5.17.1. Overview
10.5.17.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18. North Dakota
10.5.18.1. Overview
10.5.18.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19. South Dakota
10.5.19.1. Overview
10.5.19.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed four-region and all-50-state analysis, helping clients identify diabetes burden hotspots, AI-device adoption centers, CGM and AID opportunities, payer-access differences, health-system demand pockets and priority state-level commercial opportunities.

11. U.S. AI-Enabled Diabetes Care Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging Players
11.4. Competitive Analysis by Capability
11.4.1. CGM Technology Leadership
11.4.2. Automated Insulin Delivery Leadership
11.4.3. AI and Algorithm Differentiation
11.4.4. Device Interoperability
11.4.5. Type 2 Diabetes Expansion Strategy
11.4.6. Medicare and Commercial Market Access
11.4.7. Direct-to-Consumer and OTC Strategy
11.4.8. Clinical Evidence Generation
11.4.9. Digital Health Integration
11.5. Company Profiles
11.5.1. Abbott Diabetes Care
11.5.2. Dexcom, Inc.
11.5.3. Insulet Corporation
11.5.4. MiniMed / Medtronic Diabetes
11.5.5. Tandem Diabetes Care, Inc.
11.5.6. Beta Bionics, Inc.
11.5.7. Senseonics Holdings, Inc.
11.5.8. Ascensia Diabetes Care
11.5.9. Sequel Med Tech
11.5.10. Roche Diabetes Care
11.5.11. LifeScan, Inc.
11.5.12. embecta Corp.
11.5.13. Glooko, Inc.
11.5.14. Welldoc, Inc.
11.5.15. DarioHealth Corp.
11.5.16. Teladoc Health / Livongo
11.5.17. Omada Health
11.5.18. Tidepool
11.5.19. i-SENS, Inc.
11.5.20. AgaMatrix, Inc.
11.5.21. Trividia Health, Inc.
11.5.22. Novo Nordisk – Connected Insulin Device Ecosystem
11.5.23. Eli Lilly and Company – Connected Diabetes Device Ecosystem
11.5.24. Ypsomed
11.5.25. Diabeloop

Note: Each company profile should include company overview, U.S. diabetes device portfolio, AI and algorithm capabilities, CGM/AID or connected-device positioning, U.S. market strategy, financial positioning where available, FDA/regulatory developments, reimbursement strategy, interoperability partnerships, product pipeline and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, AI capability positioning, device portfolio intelligence, interoperability strategy and commercial insights on 25 important participants across the U.S. AI-enabled diabetes care ecosystem.

12. U.S. AI-Enabled Diabetes Care Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Fully and Highly Automated Insulin Delivery
12.2.2. AI-Enabled Type 2 Diabetes Insulin Automation
12.2.3. Next-Generation Continuous Glucose Monitoring
12.2.4. Long-Wear and Implantable Biosensors
12.2.5. CGM-Informed Insulin Titration Algorithms
12.2.6. Predictive Hypoglycemia and Hyperglycemia Prevention
12.2.7. AI-Based Meal Recognition and Carbohydrate Estimation
12.2.8. Multi-Biomarker Metabolic Sensors
12.2.9. Edge AI and On-Device Decision Support
12.2.10. Generative AI for Diabetes Clinical Workflow
12.2.11. Digital Twins and Personalized Glucose Response Modeling
12.2.12. Remote Autonomous Diabetes Management
12.3. Emerging Business Trends
12.4. Shift from Device Sales to Connected Ecosystem Economics
12.5. Consumerization of Glucose Monitoring
12.6. Type 2 Diabetes as the Next Major AID Growth Pool
12.7. Business Opportunities for Startups and Existing Players
12.8. Investment Prioritization Matrix
12.9. Technology Adoption Curve, 2026–2035
12.10. Market White-Space Analysis

What this section provides: This section prepares clients for technological disruption, future adoption scenarios, addressable market expansion, investment opportunities and structural changes expected to reshape U.S. AI-enabled diabetes care through 2035.

13. U.S. AI-Enabled Diabetes Care Devices Market: Strategic Recommendations

13.1. Recommendations for Diabetes Device Manufacturers
13.2. Recommendations for CGM Manufacturers
13.3. Recommendations for Insulin Pump and AID Manufacturers
13.4. Recommendations for AI and Diabetes Software Developers
13.5. Recommendations for Hospitals & Integrated Health Systems
13.6. Recommendations for Endocrinology and Diabetes Practices
13.7. Recommendations for Primary Care Organizations
13.8. Recommendations for Medicare and Commercial Payers
13.9. Recommendations for Retail Pharmacy and DME Channels
13.10. Recommendations for Investors and Private Equity Firms
13.11. Recommendations for New Entrants and Startups
13.12. Go-to-Market Strategy Considerations
13.13. Product Positioning Strategy
13.14. Type 2 Diabetes Expansion Strategy
13.15. Interoperability and Partnership Strategy
13.16. Reimbursement and Market Access Strategy
13.17. Clinical Evidence and Real-World Evidence Strategy
13.18. Geographic Expansion Prioritization
13.19. Product Portfolio Expansion Guidance

What this section provides: This section converts market intelligence into actionable recommendations for product development, commercialization, reimbursement, partnerships, state prioritization, competitive differentiation and long-term growth planning.

14. U.S. AI-Enabled Diabetes Care Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Market Definition Limitation
14.3. Data Use Limitation
14.4. AI-Enabled Device Classification Limitation
14.5. Forecasting Limitation
14.6. Regulatory and Reimbursement Information Limitation
14.7. Company and Competitive Intelligence Limitation
14.8. Legal Disclaimer
14.9. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s analytical boundaries, AI-device classification methodology, data limitations, forecasting assumptions, regulatory limitations and legal terms governing interpretation and use of the market intelligence.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. AI-Enabled Diabetes Care Devices Market: Market Definition and Scope
TABLE 3: U.S. AI-Enabled Diabetes Care Devices Market: Research Methodology Framework
TABLE 4: U.S. AI-Enabled Diabetes Care Devices Market: AI-Enabled Device Inclusion and Exclusion Criteria
TABLE 5: U.S. AI-Enabled Diabetes Care Devices Market: Key Assumptions
TABLE 6: U.S. AI-Enabled Diabetes Care Devices Market: Market Ecosystem and Stakeholder Analysis
TABLE 7: U.S. AI-Enabled Diabetes Care Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. AI-Enabled Diabetes Care Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. AI-Enabled Diabetes Care Devices Market: Market Attractiveness Index
TABLE 10: U.S. AI-Enabled Diabetes Care Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. AI-Enabled Diabetes Care Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. AI-Enabled Diabetes Care Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. AI-Enabled Diabetes Care Devices Market: High-Growth Opportunity Areas
TABLE 14: U.S. AI-Enabled Diabetes Care Devices Market: Drivers; Impact Analysis
TABLE 15: U.S. AI-Enabled Diabetes Care Devices Market: Restraints; Impact Analysis
TABLE 16: U.S. AI-Enabled Diabetes Care Devices Market: Opportunities; Impact Analysis
TABLE 17: U.S. AI-Enabled Diabetes Care Devices Market: Challenges; Impact Analysis
TABLE 18: U.S. AI-Enabled Diabetes Care Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. AI-Enabled Diabetes Care Devices Market: AI Algorithm Innovation Landscape
TABLE 20: U.S. AI-Enabled Diabetes Care Devices Market: Clinical Workflow Economics Matrix
TABLE 21: U.S. AI-Enabled Diabetes Care Devices Market: Diabetes Technology Adoption Economics
TABLE 22: U.S. AI-Enabled Diabetes Care Devices Market: Payer and Health System Value Proposition Matrix
TABLE 23: U.S. AI-Enabled Diabetes Care Devices Market: Patient Lifetime Device Economics
TABLE 24: U.S. AI-Enabled Diabetes Care Devices Market: PESTEL Analysis
TABLE 25: U.S. AI-Enabled Diabetes Care Devices Market: Porter’s Five Forces Analysis
TABLE 26: U.S. AI-Enabled Diabetes Care Devices Market: Pricing Trend Analysis, 2025–2035
TABLE 27: U.S. AI-Enabled Diabetes Care Devices Market: Value Chain Analysis
TABLE 28: U.S. AI-Enabled Diabetes Care Devices Market: Supply Chain Analysis
TABLE 29: U.S. AI-Enabled Diabetes Care Devices Market: Digitalization and Connected Diabetes Care Impact
TABLE 30: U.S. AI-Enabled Diabetes Care Devices Market: AI & Machine Learning Application Landscape
TABLE 31: U.S. AI-Enabled Diabetes Care Devices Market: Device Interoperability Landscape
TABLE 32: U.S. AI-Enabled Diabetes Care Devices Market: FDA Regulatory Framework Analysis
TABLE 33: U.S. AI-Enabled Diabetes Care Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 34: U.S. AI-Enabled Diabetes Care Devices Market: Medicare CGM Coverage Evolution
TABLE 35: U.S. AI-Enabled Diabetes Care Devices Market: Commercial Payer Coverage Landscape
TABLE 36: U.S. AI-Enabled Diabetes Care Devices Market: Cybersecurity and Data Privacy Risk Matrix
TABLE 37: U.S. AI-Enabled Diabetes Care Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 38: U.S. AI-Enabled Diabetes Care Devices Market: Government Diabetes Programs and Initiatives
TABLE 39: U.S. AI-Enabled Diabetes Care Devices Market: Health System Technology Assessment Framework
TABLE 40: U.S. AI-Enabled Diabetes Care Devices Market: Product Category Snapshot, 2025
TABLE 41: Segment Dashboard; Definition and Scope, by Product Category
TABLE 42: U.S. AI-Enabled Diabetes Care Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 43: U.S. AI-Enabled Diabetes Care Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 44: AI-Enabled Continuous Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: Automated Insulin Delivery Systems & Smart Insulin Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: Connected Insulin Pens & Intelligent Dosing Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: AI-Enabled Glucose Meters & Connected Biosensors Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: Device-Linked Diabetes Intelligence Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. AI-Enabled Diabetes Care Devices Market: Application Snapshot, 2025
TABLE 50: Segment Dashboard; Definition and Scope, by Application
TABLE 51: U.S. AI-Enabled Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 52: U.S. AI-Enabled Diabetes Care Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 53: Automated Insulin Dosing & Insulin Optimization Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: Glucose Prediction & Intelligent Alerting Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: Hypoglycemia Prevention & Safety Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: Personalized Lifestyle & Meal-Response Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: Remote Monitoring & Population Risk Stratification Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. AI-Enabled Diabetes Care Devices Market: End User Snapshot, 2025
TABLE 59: Segment Dashboard; Definition and Scope, by End User
TABLE 60: U.S. AI-Enabled Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 61: U.S. AI-Enabled Diabetes Care Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 62: Hospitals & Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: Endocrinology & Diabetes Specialty Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: Primary Care Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: Home Users & Patients Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: Remote Patient Monitoring & Digital Health Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. AI-Enabled Diabetes Care Devices Market: Technology Type Snapshot, 2025
TABLE 68: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 69: U.S. AI-Enabled Diabetes Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 70: U.S. AI-Enabled Diabetes Care Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 71: Machine Learning & Predictive Analytics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: Adaptive Control & Closed-Loop Algorithms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: Computer Vision & Intelligent Meal Recognition Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: Cloud AI & Population Analytics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: Edge Intelligence & Sensor Fusion Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. AI-Enabled Diabetes Care Devices Market: Market Access Snapshot, 2025
TABLE 77: U.S. AI-Enabled Diabetes Care Devices Market: Medicare Coverage Pathways
TABLE 78: U.S. AI-Enabled Diabetes Care Devices Market: Medicaid Coverage Landscape
TABLE 79: U.S. AI-Enabled Diabetes Care Devices Market: Commercial Insurance Coverage Landscape
TABLE 80: U.S. AI-Enabled Diabetes Care Devices Market: Pharmacy Benefit vs. DME Benefit Economics
TABLE 81: U.S. AI-Enabled Diabetes Care Devices Market: Prior Authorization Requirements
TABLE 82: U.S. AI-Enabled Diabetes Care Devices Market: Retail Pharmacy Distribution Model
TABLE 83: U.S. AI-Enabled Diabetes Care Devices Market: Durable Medical Equipment Distribution Model
TABLE 84: U.S. AI-Enabled Diabetes Care Devices Market: Direct-to-Patient Fulfillment Model
TABLE 85: U.S. AI-Enabled Diabetes Care Devices Market: Health System Procurement Dynamics
TABLE 86: U.S. AI-Enabled Diabetes Care Devices Market: Primary Care Prescribing Barriers
TABLE 87: U.S. AI-Enabled Diabetes Care Devices Market: OTC Glucose Biosensor Commercialization Pathway
TABLE 88: U.S. AI-Enabled Diabetes Care Devices Market: Reimbursement Risk Assessment, 2026–2035
TABLE 89: U.S. AI-Enabled Diabetes Care Devices Market: Regional Snapshot, 2025
TABLE 90: Segment Dashboard; Definition and Scope, by Geography
TABLE 91: U.S. AI-Enabled Diabetes Care Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 92: U.S. AI-Enabled Diabetes Care Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 93: West Region U.S. AI-Enabled Diabetes Care Devices Market: Regional Overview and Trends
TABLE 94: West Region U.S. AI-Enabled Diabetes Care Devices Market: Diabetes Burden and Addressable Patient Analysis
TABLE 95: West Region U.S. AI-Enabled Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 96: California AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Washington AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Arizona AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Colorado AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Oregon AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Utah AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Nevada AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: New Mexico AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Idaho AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Montana AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Wyoming AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Alaska AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Hawaii AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Northeast Region U.S. AI-Enabled Diabetes Care Devices Market: Regional Overview and Trends
TABLE 110: Northeast Region U.S. AI-Enabled Diabetes Care Devices Market: Diabetes Burden and Addressable Patient Analysis
TABLE 111: Northeast Region U.S. AI-Enabled Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 112: Northeast Region U.S. AI-Enabled Diabetes Care Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 113: Northeast Region U.S. AI-Enabled Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 114: Northeast Region U.S. AI-Enabled Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 115: Northeast Region U.S. AI-Enabled Diabetes Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 116: New York AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Massachusetts AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: New Jersey AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Pennsylvania AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Connecticut AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Maine AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Vermont AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: New Hampshire AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: Rhode Island AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Delaware AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: South Region U.S. AI-Enabled Diabetes Care Devices Market: Regional Overview and Trends
TABLE 127: South Region U.S. AI-Enabled Diabetes Care Devices Market: Diabetes Burden and Addressable Patient Analysis
TABLE 128: South Region U.S. AI-Enabled Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 129: South Region U.S. AI-Enabled Diabetes Care Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 130: South Region U.S. AI-Enabled Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 131: South Region U.S. AI-Enabled Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 132: South Region U.S. AI-Enabled Diabetes Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 133: Texas AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Florida AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: Georgia AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: North Carolina AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Tennessee AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: South Carolina AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Alabama AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Mississippi AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Louisiana AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Arkansas AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Kentucky AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Oklahoma AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Virginia AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Maryland AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: West Virginia AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Midwest Region U.S. AI-Enabled Diabetes Care Devices Market: Regional Overview and Trends
TABLE 149: Midwest Region U.S. AI-Enabled Diabetes Care Devices Market: Diabetes Burden and Addressable Patient Analysis
TABLE 150: Midwest Region U.S. AI-Enabled Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 151: Midwest Region U.S. AI-Enabled Diabetes Care Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 152: Midwest Region U.S. AI-Enabled Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 153: Midwest Region U.S. AI-Enabled Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 154: Midwest Region U.S. AI-Enabled Diabetes Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 155: Illinois AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Ohio AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 157: Michigan AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: Minnesota AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Indiana AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Wisconsin AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: Missouri AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: Iowa AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: Kansas AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: Nebraska AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 165: North Dakota AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 166: South Dakota AI-Enabled Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: U.S. AI-Enabled Diabetes Care Devices Market: Competitive Landscape Snapshot, 2025
TABLE 168: U.S. AI-Enabled Diabetes Care Devices Market: Key Company Market Share Analysis, 2025
TABLE 169: U.S. AI-Enabled Diabetes Care Devices Market: Company Positioning Matrix
TABLE 170: U.S. AI-Enabled Diabetes Care Devices Market: AI Capability and Product Portfolio Benchmarking
TABLE 171: U.S. AI-Enabled Diabetes Care Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 172: Abbott Diabetes Care: Company Profile
TABLE 173: Dexcom, Inc.: Company Profile
TABLE 174: Insulet Corporation: Company Profile
TABLE 175: MiniMed / Medtronic Diabetes: Company Profile
TABLE 176: Tandem Diabetes Care, Inc.: Company Profile
TABLE 177: Beta Bionics, Inc.: Company Profile
TABLE 178: Senseonics Holdings, Inc.: Company Profile
TABLE 179: Ascensia Diabetes Care: Company Profile
TABLE 180: Sequel Med Tech: Company Profile
TABLE 181: Roche Diabetes Care: Company Profile
TABLE 182: LifeScan, Inc.: Company Profile
TABLE 183: embecta Corp.: Company Profile
TABLE 184: Glooko, Inc.: Company Profile
TABLE 185: Welldoc, Inc.: Company Profile
TABLE 186: DarioHealth Corp.: Company Profile
TABLE 187: Teladoc Health / Livongo: Company Profile
TABLE 188: Omada Health: Company Profile
TABLE 189: Tidepool: Company Profile
TABLE 190: i-SENS, Inc.: Company Profile
TABLE 191: AgaMatrix, Inc.: Company Profile
TABLE 192: Trividia Health, Inc.: Company Profile
TABLE 193: Novo Nordisk – Connected Insulin Device Ecosystem: Company Profile
TABLE 194: Eli Lilly and Company – Connected Diabetes Device Ecosystem: Company Profile
TABLE 195: Ypsomed: Company Profile
TABLE 196: Diabeloop: Company Profile
TABLE 197: U.S. AI-Enabled Diabetes Care Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 198: U.S. AI-Enabled Diabetes Care Devices Market: Disruptive Technologies Impact Matrix
TABLE 199: U.S. AI-Enabled Diabetes Care Devices Market: Type 2 Diabetes AID Expansion Opportunity
TABLE 200: U.S. AI-Enabled Diabetes Care Devices Market: Next-Generation CGM and Biosensor Opportunity
TABLE 201: U.S. AI-Enabled Diabetes Care Devices Market: Emerging Business Trends
TABLE 202: U.S. AI-Enabled Diabetes Care Devices Market: Business Opportunities for Startups and Existing Players
TABLE 203: U.S. AI-Enabled Diabetes Care Devices Market: Investment Prioritization Matrix
TABLE 204: U.S. AI-Enabled Diabetes Care Devices Market: Market White-Space Analysis
TABLE 205: U.S. AI-Enabled Diabetes Care Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 206: U.S. AI-Enabled Diabetes Care Devices Market: Strategic Recommendations for Hospitals and Health Systems
TABLE 207: U.S. AI-Enabled Diabetes Care Devices Market: Strategic Recommendations for Payers
TABLE 208: U.S. AI-Enabled Diabetes Care Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 209: U.S. AI-Enabled Diabetes Care Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 210: U.S. AI-Enabled Diabetes Care Devices Market: Go-to-Market Strategy Considerations
TABLE 211: U.S. AI-Enabled Diabetes Care Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 212: U.S. AI-Enabled Diabetes Care Devices Market: Scope Limitation
TABLE 213: U.S. AI-Enabled Diabetes Care Devices Market: Market Definition Limitation
TABLE 214: U.S. AI-Enabled Diabetes Care Devices Market: Data Use Limitation
TABLE 215: U.S. AI-Enabled Diabetes Care Devices Market: AI-Enabled Device Classification Limitation
TABLE 216: U.S. AI-Enabled Diabetes Care Devices Market: Forecasting Limitation
TABLE 217: U.S. AI-Enabled Diabetes Care Devices Market: Regulatory and Reimbursement Information Limitation
TABLE 218: U.S. AI-Enabled Diabetes Care Devices Market: Competitive Intelligence Limitation
TABLE 219: U.S. AI-Enabled Diabetes Care Devices Market: Legal Disclaimer
TABLE 220: U.S. AI-Enabled Diabetes Care Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. AI-Enabled Diabetes Care Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: U.S. AI-Enabled Diabetes Care Devices Market Ecosystem
FIGURE 4: Stakeholder Analysis Framework
FIGURE 5: U.S. AI-Enabled Diabetes Care Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 6: U.S. AI-Enabled Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 7: U.S. AI-Enabled Diabetes Care Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 8: Market Attractiveness Analysis
FIGURE 9: U.S. AI-Enabled Diabetes Care Devices Market Dynamics
FIGURE 10: Innovation & Patent Landscape, 2021–2025
FIGURE 11: AI Algorithm Innovation Roadmap
FIGURE 12: Clinical Workflow Economics Framework
FIGURE 13: Diabetes Technology Adoption Economics Framework
FIGURE 14: PESTEL Analysis
FIGURE 15: Porter’s Five Forces Analysis
FIGURE 16: Value Chain Analysis
FIGURE 17: Supply Chain Analysis
FIGURE 18: AI & Machine Learning Application Landscape
FIGURE 19: FDA, Reimbursement and Connected Device Regulatory Framework
FIGURE 20: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 21: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: AI-Enabled Continuous Glucose Monitoring Systems Market Forecast, 2021–2035
FIGURE 23: Automated Insulin Delivery Systems & Smart Insulin Pumps Market Forecast, 2021–2035
FIGURE 24: Connected Insulin Pens & Intelligent Dosing Systems Market Forecast, 2021–2035
FIGURE 25: AI-Enabled Glucose Meters & Connected Biosensors Market Forecast, 2021–2035
FIGURE 26: Device-Linked Diabetes Intelligence Platforms Market Forecast, 2021–2035
FIGURE 27: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 28: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Automated Insulin Dosing & Insulin Optimization Market Forecast, 2021–2035
FIGURE 30: Glucose Prediction & Intelligent Alerting Market Forecast, 2021–2035
FIGURE 31: Hypoglycemia Prevention & Safety Management Market Forecast, 2021–2035
FIGURE 32: Personalized Lifestyle & Meal-Response Management Market Forecast, 2021–2035
FIGURE 33: Remote Monitoring & Population Risk Stratification Market Forecast, 2021–2035
FIGURE 34: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 35: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Hospitals & Integrated Health Systems Market Forecast, 2021–2035
FIGURE 37: Endocrinology & Diabetes Specialty Centers Market Forecast, 2021–2035
FIGURE 38: Primary Care Practices Market Forecast, 2021–2035
FIGURE 39: Home Users & Patients Market Forecast, 2021–2035
FIGURE 40: Remote Patient Monitoring & Digital Health Providers Market Forecast, 2021–2035
FIGURE 41: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 42: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Machine Learning & Predictive Analytics Market Forecast, 2021–2035
FIGURE 44: Adaptive Control & Closed-Loop Algorithms Market Forecast, 2021–2035
FIGURE 45: Computer Vision & Intelligent Meal Recognition Market Forecast, 2021–2035
FIGURE 46: Cloud AI & Population Analytics Market Forecast, 2021–2035
FIGURE 47: Edge Intelligence & Sensor Fusion Market Forecast, 2021–2035
FIGURE 48: U.S. AI-Enabled Diabetes Care Devices Market Access Framework
FIGURE 49: Medicare, Medicaid and Commercial Payer Coverage Landscape
FIGURE 50: Pharmacy Benefit vs. DME Benefit Pathway
FIGURE 51: U.S. Diabetes Device Distribution and Fulfillment Ecosystem
FIGURE 52: OTC Glucose Biosensor Commercialization Pathway
FIGURE 53: Reimbursement Risk Outlook, 2026–2035
FIGURE 54: Regional Market Share Analysis, 2025 & 2035
FIGURE 55: Regional Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: West Region Market Share Analysis by State, 2025
FIGURE 57: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: California AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 59: Washington AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 60: Arizona AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 61: Colorado AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 62: Oregon AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 63: Utah AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 64: Nevada AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 65: New Mexico AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 66: Idaho AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 67: Montana AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 68: Wyoming AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 69: Alaska AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 70: Hawaii AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 71: Northeast Region Market Share Analysis by State, 2025
FIGURE 72: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New York AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 74: Massachusetts AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 75: New Jersey AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 76: Pennsylvania AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 77: Connecticut AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 78: Maine AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 79: Vermont AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 80: New Hampshire AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 81: Rhode Island AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 82: Delaware AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 83: South Region Market Share Analysis by State, 2025
FIGURE 84: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Texas AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 86: Florida AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 87: Georgia AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 88: North Carolina AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 89: Tennessee AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 90: South Carolina AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 91: Alabama AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 92: Mississippi AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 93: Louisiana AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 94: Arkansas AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 95: Kentucky AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 96: Oklahoma AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 97: Virginia AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 98: Maryland AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 99: West Virginia AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 100: Midwest Region Market Share Analysis by State, 2025
FIGURE 101: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Illinois AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 103: Ohio AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 104: Michigan AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 105: Minnesota AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 106: Indiana AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 107: Wisconsin AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 108: Missouri AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 109: Iowa AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 110: Kansas AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 111: Nebraska AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 112: North Dakota AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 113: South Dakota AI-Enabled Diabetes Care Devices Market Forecast, 2021–2035
FIGURE 114: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 115: Company Positioning Matrix
FIGURE 116: AI Capability and Product Portfolio Benchmarking of Key Players
FIGURE 117: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 118: U.S. AI-Enabled Diabetes Care Device Innovation Roadmap
FIGURE 119: Automated Insulin Delivery Adoption Roadmap
FIGURE 120: Type 2 Diabetes AI-Enabled Device Opportunity Map
FIGURE 121: Next-Generation CGM and Biosensor Technology Roadmap
FIGURE 122: Future Market Scenario Analysis, 2026–2035
FIGURE 123: Disruptive Technologies Impact Matrix
FIGURE 124: Emerging Business Trends Matrix
FIGURE 125: Investment Prioritization and Market White-Space Matrix
FIGURE 126: Strategic Growth Roadmap for U.S. AI-Enabled Diabetes Device Companies
FIGURE 127: Go-to-Market and Market Access Strategy Framework
FIGURE 128: Product Positioning, Interoperability and Portfolio Expansion Framework
FIGURE 129: Report Scope, Data Limitation and Disclaimer Framework